Advanced

Antimuscarinics for treatment of overactive bladder

Andersson, Karl-Erik LU (2004) In Lancet Neurology 3(1). p.46-53
Abstract
For many years, antimuscarinic drugs have been the first-line pharmacological treatment for urgency, frequency, and urge incontinence, all symptoms of the disorder termed overactive bladder. Antimuscarinic treatment is not always effective and is associated with side-effects that limit its clinical use. The clinical significance of the effects of antimuscarinic drugs has been questioned lately. In this review, the rationale for the use of these drugs in the management of overactive bladder is re-examined and the results of treatment are discussed. I conclude that these drugs are the only treatment with undisputed effectiveness in the treatment of overactive bladder. They may not be the perfect treatment for all patients with this disorder,... (More)
For many years, antimuscarinic drugs have been the first-line pharmacological treatment for urgency, frequency, and urge incontinence, all symptoms of the disorder termed overactive bladder. Antimuscarinic treatment is not always effective and is associated with side-effects that limit its clinical use. The clinical significance of the effects of antimuscarinic drugs has been questioned lately. In this review, the rationale for the use of these drugs in the management of overactive bladder is re-examined and the results of treatment are discussed. I conclude that these drugs are the only treatment with undisputed effectiveness in the treatment of overactive bladder. They may not be the perfect treatment for all patients with this disorder, but their value for individual patients should not be underestimated. Further clinical trials with improvement in quality of life as the primary endpoint are needed and may give a fair reflection of the clinical value of antimuscarinic drugs. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Lancet Neurology
volume
3
issue
1
pages
46 - 53
publisher
Lancet Ltd
external identifiers
  • pmid:14693111
  • wos:000187447100025
  • scopus:0346250806
ISSN
1474-4465
DOI
10.1016/S1474-4422(03)00622-7
language
English
LU publication?
yes
id
83f1ac6c-a9fb-4985-b1f9-df5277025340 (old id 291320)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14693111&dopt=Abstract
date added to LUP
2007-08-02 10:04:11
date last changed
2017-11-19 03:38:13
@article{83f1ac6c-a9fb-4985-b1f9-df5277025340,
  abstract     = {For many years, antimuscarinic drugs have been the first-line pharmacological treatment for urgency, frequency, and urge incontinence, all symptoms of the disorder termed overactive bladder. Antimuscarinic treatment is not always effective and is associated with side-effects that limit its clinical use. The clinical significance of the effects of antimuscarinic drugs has been questioned lately. In this review, the rationale for the use of these drugs in the management of overactive bladder is re-examined and the results of treatment are discussed. I conclude that these drugs are the only treatment with undisputed effectiveness in the treatment of overactive bladder. They may not be the perfect treatment for all patients with this disorder, but their value for individual patients should not be underestimated. Further clinical trials with improvement in quality of life as the primary endpoint are needed and may give a fair reflection of the clinical value of antimuscarinic drugs.},
  author       = {Andersson, Karl-Erik},
  issn         = {1474-4465},
  language     = {eng},
  number       = {1},
  pages        = {46--53},
  publisher    = {Lancet Ltd},
  series       = {Lancet Neurology},
  title        = {Antimuscarinics for treatment of overactive bladder},
  url          = {http://dx.doi.org/10.1016/S1474-4422(03)00622-7},
  volume       = {3},
  year         = {2004},
}